Other substances

Dornase alfa

A recombinant form of the human DNase I enzyme.

Phase of research

Potential treatment - clinical evidence

How it helps

Other treatment

Drug status

Used to treat other disease

2
 Supporting references
0
 Contradictory references
2
 AI-suggested references
10
 Clinical trials

General information

Dornase alfa is a recombinant form of the human DNase I enzyme, which is used in cystic fibrosis patients to degrade neutrophil extracellular traps and thereby reduce the viscoelasticity of secretions in the respiratory tract (Okur et al., 2020).

Dornase alfa on DrugBank
Dornase alfa on Wikipedia

Marketed as

PULMOZYME; VISCOZYME

 

Supporting references

Link Tested on Impact factor Notes Publication date
Nebulized in-line endotracheal dornase alfa and albuterol administered to mechanically ventilated COVID-19 patients: A case series
Preprint Case series 		Patients

Following nebulized in-line administration of dornase alfa with albuterol, the fraction of inspired oxygen requirements was reduced for all five patients

 May/15/2020
Preliminary report of in vitro and in vivo effectiveness of dornase alfa on SARS-CoV-2 infection
Protein factor Case series 		Vero E6 cells; MDBK cell line; Patients 0.60

Inhibited SARS-CoV-2 in vitro and improved breathing (and some other clinical parameters) in a small case series of patients. Sample size: 3. Dosage: 2.5 mg (in a jet nebulizer) daily for 3 days.

 Sep/07/2020

AI-suggested references

Link Publication date
Non-Randomized Trial of Dornase Alfa for Acute Respiratory Distress Syndrome Secondary to Covid-19
Oct/20/2021
The Use of Dornase Alfa in the Management of COVID-19-Associated Adult Respiratory Distress Syndrome.
Apr/23/2021

Clinical trials

ID Title Status Phase Start date Completion date
NCT04387786 Dornase Alfa Administered to Patients With COVID-19 (DACOVID) Completed Mar/31/2020 Sep/04/2020
  • Alternative id - 216
  • Interventions - Drug: Dornase Alfa
  • Study type - Observational
  • Study results - No Results Available
  • Locations - Feinstein Insitute for Medical Research at Northwell Health, Manhasset, New York, United States
  • Study designs - Observational Model: Case-Only|Time Perspective: Retrospective
  • Enrollment - 5
  • Age - 18 Years to 85 Years   (Adult, Older Adult)
  • Outcome measures - Number of participants discharged from the intensive care unit (ICU)|Number of participants who survived COVID-19|Mean change in FiO2
NCT04432987 Dornase Alpha for the Treatment of COVID-19 Recruiting Phase 2 May/25/2020 Sep/25/2020
  • Alternative id - 8820
  • Interventions - Drug: Pulmozyme
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Acıbadem Altunizade Hospital, Istanbul, Turkey
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  • Enrollment - 60
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - Response|Survival
NCT04488081 I-SPY COVID-19 TRIAL: An Adaptive Platform Trial for Critically Ill Patients Recruiting Phase 2 Jul/31/2020 Nov/01/2022
  • Alternative id - I-SPY-COVID
  • Interventions - Drug: Remdesivir|Drug: Pulmozyme|Drug: IC14|Drug: Celecoxib Famotidine|Drug: Narsoplimab|Drug: Aviptadil Acetate|Drug: Cyclosporine
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - University of Alabama at Birmingham, Birmingham, Alabama, United States|UC Davis Medical Center, Davis, California, United States|Long Beach Memorial Medical Center, Long Beach, California, United States|University of Southern California, Los Angeles, California, United States|Hoag Memorial Hospital Presbyterian, Newport Beach, California, United States|University of California San Francisco (UCSF), San Francisco, California, United States|University of Colorado, Aurora, Colorado, United States|Yale Cancer Center, New Haven, Connecticut, United States|Georgetown University, Washington, District of Columbia, United States|Emory University, Atlanta, Georgia, United States|Northwestern University, Chicago, Illinois, United States|University of Iowa, Iowa City, Iowa, United States|Kalispell Regional Medical Center, Kalispell, Montana, United States|Montefiore Medical Center, Bronx, New York, United States|Columbia University Medical Center, New York, New York, United States|Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem, North Carolina, United States|University of Pennsylvania (U Penn), Philadelphia, Pennsylvania, United States|Main Line Health - Lankenau Medical Center, Wynnewood, Pennsylvania, United States|Sanford Health, Sioux Falls, South Dakota, United States
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  • Enrollment - 1500
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - Identify agents that will result in substantial improvements to the clinical condition of participants with COVID-19|Improvement in disease severity|Health care utilization|Frequency of serious AEs|Mortality
NCT04402970 Dornase Alfa for ARDS in Patients With Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2) Completed Phase 3 Jun/19/2020 Dec/31/2020
  • Alternative id - 2022206
  • Interventions - Drug: Dornase Alfa Inhalation Solution
  • Study type - Interventional
  • Study results - Has Results
  • Locations - University of Missouri Hospital and Clinics, Columbia, Missouri, United States
  • Study designs - Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment
  • Enrollment - 30
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - Change in Arterial Blood Oxygen Content to Fraction of Inspired Oxygen Ratio (PaO2/FiO2)|Change in Static Lung Compliance|Duration of Mechanical Ventilation|Length of ICU Stay|Length of Hospitalization|Secondary Bacterial Infections|Mortality
NCT04445285 Phase 2 Trial Using rhDNase to Reduce Mortality in COVID-19 Patients With Respiratory Failure Recruiting Phase 2 Apr/28/2020 Feb/28/2022
  • Alternative id - USAH 1002 000
  • Interventions - Drug: Pulmozyme/ Recombinant human deoxyribonuclease (rh-DNase)|Drug: 0.9%sodium chloride
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - University of South Alabama, Mobile, Alabama, United States
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment
  • Enrollment - 44
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - Mortality at 28 days|Systemic Therapeutic Response|Respiratory Response|Legnth of ICU Stay|Legnth of Hospital Stay|Pulmonary Function
NCT04355364 Efficacy and Safety of aerosolizedDornase Alfa Administration in Patients With COVID19 Induced ARDS (COVIDORNASE) Terminated Phase 3 Apr/21/2020 Dec/20/2021
  • Alternative id - CGE_2020_9
  • Interventions - Drug: Dornase Alfa Inhalation Solution [Pulmozyme]|Procedure: standard procedure
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Hôpital Fondation A. de Rotschhild, Paris, France
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment
  • Enrollment - 77
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - Efficacy of intratracheal administration: occurrence of at least one grade improvement
NCT04402944 Pulmozyme to Improve COVID-19 ARDS Outcomes Recruiting Phase 2 Jul/05/2020 Dec/31/2021
  • Alternative id - P00035140
  • Interventions - Drug: Pulmozyme|Drug: Placebo
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Boston Children's Hospital, Boston, Massachusetts, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|South Shore Hospital, Weymouth, Massachusetts, United States
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment
  • Enrollment - 60
  • Age - 3 Years and older   (Child, Adult, Older Adult)
  • Outcome measures - Ventilator-free days at 28 days|change in airway resistance|change in lung compliance|oxygenation (PaO2/FiO2 ratio)|length of stay (ICU and hospital)|rate of barotrauma|mortality.
NCT05139901 Usefulness of DORNASE in COVID-19 on HFNO Not yet recruiting Phase 4 Dec/01/2021 Jun/01/2022
  • Alternative id - DTS_pulmosyme
  • Interventions - Drug: Dornase Alfa|Drug: Saline
  • Study type - Interventional
  • Study results - No Results Available
  • Locations -
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment
  • Enrollment - 60
  • Age - 18 Years to 100 Years   (Adult, Older Adult)
  • Outcome measures - Intubations|PaO2/FiO2|inflamation
NCT05279391 Combination of Inhaled DNase, Baricitinib and Tocilizumab in Severe COVID-19 Recruiting Not Applicable Oct/25/2020 Dec/31/2023
  • Alternative id - 87/08-04-2020|16210/20-04-2021
  • Interventions - Drug: Dexamethasone|Drug: Low molecular weight heparin|Drug: Anakinra 100Mg/0.67Ml Inj Syringe|Drug: Tocilizumab|Drug: Baricitinib|Drug: Dornase Alfa Inhalant Product
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - University Hospital of Alexandroupolis, Alexandroupolis, Evros, Greece
  • Study designs - Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  • Enrollment - 150
  • Age - 18 Years to 100 Years   (Adult, Older Adult)
  • Outcome measures - In-hospital mortality rate|Intubation rate|Days of hospitalization|Overall mortality rate
NCT04359654 Nebulised Dornase Alfa for Treatment of COVID-19 Completed Phase 2 Jun/16/2020 Nov/05/2021
  • Alternative id - 132333
  • Interventions - Drug: Dornase Alfa Inhalation Solution [Pulmozyme]
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - University College London Hospital, London, United Kingdom
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  • Enrollment - 41
  • Age - 18 Years to 100 Years   (Adult, Older Adult)
  • Outcome measures - Measuring the change in inflammation|Number of patients that are alive at 28 days|Amount of days that patient requires oxygen|Average oxygenation index|Days patient admitted to hospital|Percentage of patients that need mechanical ventilation
Export (.csv)